EXEL Exelixis
- 36.020
- +1.520+4.41%
- 35.170
- -0.850-2.36%
Exelixis News
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Vertex Pharmaceuticals (VRTX)
Barclays Sticks to Its Hold Rating for Exelixis (EXEL)
Positive Outlook for Exelixis Amid Strong Revenue and Clinical Developments
Exelixis: Hold Rating Amid Stable Performance and Moderate Growth Expectations
Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025
Press Release: Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025
H.C. Wainwright Maintains Exelixis(EXEL.US) With Buy Rating, Raises Target Price to $40
Express News | Exelixis, Inc. : H.c. Wainwright Raises Target Price to $40 From $29
RBC Capital Remains a Buy on Exelixis (EXEL)
Citi Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $38
Positive FDA Signal and Growth Prospects Drive Buy Rating for Exelixis
Express News | Exelixis: Snda Remains Under Consideration by FDA With Pdufa Date of April 3, 2025
Express News | Exelixis: Notified by FDA That Snda for Cabometyx to No Longer Be Subject of Discussion at Oncologic Drugs Advisory Committee Meeting
Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX) for the Treatment of Patients With Previously Treated Advanced Neuroendocrine Tumors
Exelixis Analyst Ratings
Guggenheim Maintains Exelixis(EXEL.US) With Buy Rating, Raises Target Price to $42
Exelixis, Inc. (NASDAQ:EXEL) Is Largely Controlled by Institutional Shareholders Who Own 74% of the Company
Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?
(EXEL) - Analyzing Exelixis's Short Interest
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
No Data